Laurus Labs has been transforming its business mix, reducing its dependence on anti-retroviral (ARV) drugs and expanding its contract development and manufacturing organisation (CDMO) business. Nuvama believes this shift could drive the drugmaker’s next phase of growth.
Also Read: PC Jeweller, Shanti Gold & other jewellery stocks rally up to 10%. Here’s why